Perceptive Advisors LLC holds a focused book of 92 stocks worth $5.1B as of Q1 2026 (disclosed May 29, 2026, a ~45-day 13F lag). This quarter they opened Ionis Pharmaceuticals Inc and trimmed Celcuity Inc. Their largest long position is Praxis Precision Medicines I at 13% of the equity book. They also disclosed $50.8M in put options (a bearish bet) and $4.2M in call options (bullish), shown separately below and excluded from the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1224962/holdings"
Use Arkolith to show PERCEPTIVE ADVISORS LLC's latest holdings, largest changes, and filing provenance.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
91% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Praxis Precision Medicines I COM NEW | $656.0M | 2.04M | 13.0% | ▲+2.0% Added · +40K sh | |
| 2 | Celcuity Inc COM | $356.9M | 3.13M | 7.1% | ▼−1.0% Reduced · −33K sh | |
| 3 | Ascendis Pharma A/s SPONSORED ADR | $350.3M | 1.53M | 6.9% | ▲+42% Added · +450K sh | |
| 4 | Roivant Sciences Ltd SHS | $229.5M | 8.29M | 4.5% | ▲+3.8% Added · +300K sh | |
| 5 | Centessa Pharmaceuticals PLC SPONSORED ADS | $208.9M | 5.26M | 4.1% | ▲+80% Added · +2.3M sh | |
| 6 | Rhythm Pharmaceuticals Inc COM | $206.4M | 2.37M | 4.1% | ▼−6.8% Reduced · −173K sh | |
| 7 | Spyre Therapeutics Inc COM NEW | $190.8M | 3.78M | 3.8% | ▲+23% Added · +714K sh | |
| 8 | Nuvalent Inc COM | $161.9M | 1.58M | 3.2% | ▼−5.1% Reduced · −85K sh | |
| 9 | Edgewise Therapeutics Inc COM | $139.4M | 4.42M | 2.8% | ▼−0.8% Reduced · −34K sh | |
| 10 | Protagonist Therapeutics Inc COM | $129.7M | 1.23M | 2.6% | ▼−8.8% Reduced · −120K sh | |
| 11 | Apogee Therapeutics Inc COM | $129.7M | 1.54M | 2.6% | ▼−34% Reduced · −790K sh | |
| 12 | Travere Therapeutics Inc COM | $123.1M | 4.14M | 2.4% | ▼−3.2% Reduced · −136K sh | |
| 13 | Amylyx Pharmaceuticals Inc COM | $115.2M | 8.28M | 2.3% | —Held | |
| 14 | Immatics N.V SHS | $102.2M | 10.38M | 2.0% | —Held | |
| 15 | Relay Therapeutics Inc COM | $97.0M | 9.75M | 1.9% | ▲+412% Added · +7.8M sh | |
| 16 | Inhibrx Biosciences Inc COM | $97.0M | 1.44M | 1.9% | ▼−0.7% Reduced · −10K sh | |
| 17 | Meiragtx Hldgs PLC COM | $89.3M | 10.33M | 1.8% | —Held | |
| 18 | Zymeworks Inc COM | $87.9M | 3.51M | 1.7% | ▲+7.6% Added · +248K sh | |
| 19 | Solid Biosciences Inc COM NEW | $85.7M | 11.91M | 1.7% | ▲+0.6% Added · +73K sh | |
| 20 | Dyne Therapeutics Inc COM | $84.6M | 4.67M | 1.7% | ▲+34% Added · +1.2M sh | |
| 21 | Biocryst Pharmaceuticals Inc COM | $70.8M | 7.43M | 1.4% | ▲+135% Added · +4.3M sh | |
| 22 | Oruka Therapeutics Inc COM | $68.4M | 1.40M | 1.4% | ▼−5.5% Reduced · −81K sh | |
| 23 | Artivion Inc COM | $60.0M | 1.64M | 1.2% | ▼−4.9% Reduced · −85K sh | |
| 24 | Nurix Therapeutics Inc COM | $57.5M | 3.71M | 1.1% | ▲+4.3% Added · +155K sh | |
| 25 | Nautilus Biotechnology Inc COM | $48.9M | 12.59M | 1.0% | —Held | |
| 26 | Cytomx Therapeutics Inc. COM | $47.5M | 10.10M | 0.9% | ▲+4.3% Added · +419K sh | |
| 27 | Alto Neuroscience Inc COM SHS | $45.2M | 2.01M | 0.9% | ▲+13% Added · +226K sh | |
| 28 | Engene Holdings Inc COM | $39.7M | 5.83M | 0.8% | ▼−0.7% Reduced · −42K sh | |
| 29 | Immunovant Inc COM | $39.7M | 1.60M | 0.8% | ▼−20% Reduced · −398K sh | |
| 30 | Intuitive Surgical Inc COM NEW | $39.4M | 85.4K | 0.8% | ▼−2.8% Reduced · −3K sh | |
| 31 | Ionis Pharmaceuticals Inc COM | $37.8M | 504.0K | 0.7% | ▲New New position | |
| 32 | Day One Biopharmaceuticals I COM | $37.6M | 1.76M | 0.7% | ▲New New position | |
| 33 | Abivax Sa SPONSORED ADS | $36.6M | 328.9K | 0.7% | ▼−28% Reduced · −129K sh | |
| 34 | Corvus Pharmaceuticals Inc COM | $33.5M | 2.29M | 0.7% | ▲+231% Added · +1.6M sh | |
| 35 | Repligen Corp COM | $33.1M | 280.5K | 0.7% | ▼−11% Reduced · −35K sh | |
| 36 | Jazz Pharmaceuticals PLC SHS USD | $32.1M | 170.0K | 0.6% | —Held | |
| 37 | Damora Therapeutics Inc COM NEW | $31.7M | 1.22M | 0.6% | ▲New New position | |
| 38 | X4 Pharmaceuticals Inc COM NEW | $27.8M | 6.74M | 0.5% | ▲+6.7% Added · +423K sh | |
| 39 | Guardant Health Inc COM | $27.7M | 300.0K | 0.5% | ▲+88% Added · +140K sh | |
| 40 | Bright Minds Biosciences Inc COM NEW | $27.5M | 377.5K | 0.5% | ▼−16% Reduced · −72K sh | |
| 41 | Invivyd Inc COM | $27.1M | 20.86M | 0.5% | ▼−4.2% Reduced · −926K sh | |
| 42 | Sionna Therapeutics Inc COM | $26.4M | 658.4K | 0.5% | ▼−44% Reduced · −521K sh | |
| 43 | Axsome Therapeutics Inc. COM | $25.3M | 149.9K | 0.5% | ▲+0.7% Added · +1K sh | |
| 44 | Revolution Medicines Inc COM | $25.1M | 258.6K | 0.5% | ▲New New position | |
| 45 | SAB Biotherapeutics Inc COM NEW | $24.6M | 6.43M | 0.5% | ▲+701% Added · +5.6M sh | |
| 46 | Belite Bio Inc SPONSORED ADS | $24.2M | 152.0K | 0.5% | ▼−63% Reduced · −262K sh | |
| 47 | Tenax Therapeutics Inc COM NEW | $23.2M | 1.45M | 0.5% | ▲+230% Added · +1.0M sh | |
| 48 | Axogen Inc COM | $23.1M | 697.3K | 0.5% | ▼−11% Reduced · −87K sh | |
| 49 | Viridian Therapeutics Inc COM | $22.9M | 1.17M | 0.5% | ▼−62% Reduced · −1.9M sh | |
| 50 | Orchestra Biomed Hldgs Inc COM | $21.4M | 5.04M | 0.4% | ▼−1.7% Reduced · −89K sh |
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| PUT · bearish | MODERNA INCMRNA | $50.8M | 1.0M |
| CALL · bullish | OCULAR THERAPEUTIX INCOCUL | $4.2M | 500K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 29, 2026 | 94 | $5.1B | 13F-HR/A |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 116 | $5.6B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 93 | $3.5B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 85 | $2.7B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | Aug 6, 2025 | 87 | $2.8B | 13F-HR/A |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 99 | $3.6B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 108 | $4.7B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 16, 2024 | 110 | $4.2B | 13F-HR/A |
| Q1 2024 | Mar 31, 2024 | Aug 6, 2024 | 112 | $5.7B | 13F-HR/A |
| Q4 2023 | Dec 31, 2023 | Feb 26, 2024 | 101 | $4.5B | 13F-HR/A |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 97 | $3.0B | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 24, 2023 | 95 | $3.5B | 13F-HR/A |
| Q1 2023 | Mar 31, 2023 | May 16, 2023 | 99 | $3.4B | 13F-HR/A |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 96 | $3.6B | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 | 116 | $3.4B | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 15, 2022 | 111 | $3.2B | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 16, 2022 | 135 | $5.0B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.